Press Releases and News
Other published information who is not classified as regulatory news
Orexo is celebrating 10 years on the US Pharma market - Interview with Robert DeLuca, President of Orexo US Inc.
News Release – Uppsala, Sweden, September 29, 2023
The year of 2023 marks 10 years on the US Pharma market for Orexo. In September 2013, after conscientious preparations and an FDA approval, ZUBSOLV®, became available for patients across the US. A big achievement and the start of a journey that is making a difference to the people whose lives are affected by the US opioid epidemic. In this interview, Robert DeLuca, President of Orexo US Inc., reflects on these exciting years and how he and his team are committed to tackling the opioid crisis from broad and holistic perspective.
Uppsala, Sweden – August 29, 2023 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US patent specifically related to OX640, Orexo’s nasal epinephrine powder product based on the amorphOX® drug delivery platform.
International Overdose Awareness Day, tomorrow on 31 August, is an opportunity for people across the globe to reflect on the many lives being destroyed by opioids, and the grief of their loved ones. Synthetic opioids are driving a record-high surge in fatal overdoses. With deaths caused by opioid misuse climbing to greater than 92,000[i] last year, it’s more important than ever to consider how we can prevent more broken lives.
- OX124 is designed to reverse the effect of the most powerful synthetic opioids
- Synthetic opioids are behind the majority of fatal overdoses in the US, a development expected to increase due to Covid-19
- New Drug Application (NDA) filing expected mid 2022